Vanda Pharms Inc Drug Patent Portfolio
Vanda Pharms Inc owns 4 orange book drugs protected by 49 US patents Given below is the list of Vanda Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11951097 | Methods of treating multiple sclerosis | 10 Oct, 2042 | Active |
| US11759446 | Liquid tasimelteon formulations and methods of use thereof | 21 Feb, 2041 | Active |
| US11202770 | Liquid tasimelteon formulations and methods of use thereof | 11 Dec, 2040 | Active |
| US10220023 | Dosing regimen for a selective S1P1 receptor agonist | 10 Dec, 2035 | Active |
| US10179119 | Method of treatment | 29 Aug, 2035 | Active |
| US11266622 | Method of treatment | 29 Aug, 2035 | Active |
| US10376487 | Method of treatment | 27 Jul, 2035 | Active |
| US10071977 | Highly purifid pharmaceutical grade tasimelteon | 12 Feb, 2035 | Active |
| US10829465 | Highly purified pharmaceutical grade tasimelteon | 12 Feb, 2035 | Active |
| US11566011 | Highly purified pharmaceutical grade tasimelteon | 12 Feb, 2035 | Active |
| US11760740 | Highly purified pharmaceutical grade tasimelteon | 12 Feb, 2035 | Active |
| US12049457 | Highly purified pharmaceutical grade tasimelteon | 12 Feb, 2035 | Active |
| US10610511 | Method of treatment | 10 Oct, 2034 | Active |
| US11141400 | Method of treatment | 10 Oct, 2034 | Active |
| US11786502 | Method of treatment | 10 Oct, 2034 | Active |
| US9730910 | Treatment of circadian rhythm disorders | 17 May, 2034 | Active |
| US11918556 | Treatment of circadian rhythm disorders | 07 Apr, 2033 | Active |
| US10149829 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US10449176 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US10610510 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US10945988 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US10980770 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11285129 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11633377 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11826339 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11833130 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11850229 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US11918557 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US8785492 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US9060995 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US9539234 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US9549913 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US9855241 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| USRE46604 | Treatment of circadian rhythm disorders | 25 Jan, 2033 | Active |
| US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one | 06 May, 2032 | Active |
| US9074254 | Method of predicting a predisposition to QT prolongation | 28 Dec, 2031 | Active |
| US9074256 | Method of predicting a predisposition to QT prolongation | 10 Feb, 2031 | Active |
| US9072742 | Method of predicting a predisposition to QT prolongation | 16 Jan, 2031 | Active |
| US9074255 | Method of predicting a predisposition to QT prolongation | 17 Dec, 2030 | Active |
| US8999638 | Method of treatment based on polymorphisms of the KCNQ1 gene | 28 Oct, 2030 | Active |
| US8652776 | Prediction of QT prolongation based on SNP genotype | 31 Aug, 2030 | Active |
| US9157121 | Method of treatment based on polymorphisms of the KCNQ1 gene | 05 Apr, 2030 | Active |
| US8586610 | Methods for the administration of iloperidone | 02 Nov, 2027 | Active |
| US8273779 | Thiazolidin 4-one derivatives | 17 Dec, 2025 | Active |
| USRE43728 | Thiazolidin-4-one derivatives | 16 Nov, 2025 | Active |
| US9138432 | Methods for the administration of iloperidone | 30 Sep, 2025 | Active |
| US9000018 | Thiazolidin-4-one-derivatives | 16 Nov, 2024 | Expired |
| US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents | 09 Dec, 2022 | Expired |
| USRE39198 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics | 15 Nov, 2016 | Expired |
Latest Legal Activities on Vanda Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Vanda Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539234 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9539234 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jun, 2024 | US8273779 |
|
Email Notification
Critical
| 20 Jun, 2024 | US8273779 |
|
Email Notification
Critical
| 20 Jun, 2024 | US9000018 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jun, 2024 | US9000018 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 20 Jun, 2024 | US9062014 |
|
Email Notification
Critical
| 20 Jun, 2024 | US9062014 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Jun, 2024 | US11951097 |
|
Email Notification
Critical
| 18 Jun, 2024 | US11951097 |
|
Maintenance Fee Reminder Mailed
Critical
| 13 May, 2024 | US8273779 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 May, 2024 | US10829465 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 May, 2024 | US10829465 |
| Post Issue Communication - Certificate of Correction | 08 May, 2024 | US11951097 |
|
Email Notification
Critical
| 01 May, 2024 | US11951097 |
Vanda Pharms Inc's Drug Patent Litigations
Vanda Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 26, 2016, against patent number US9138432. The petitioner Roxane Laboratories, Inc., challenged the validity of this patent, with Vanda Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Vanda Pharms Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10376487 | December, 2017 |
Decision
(13 Feb, 2019)
| Vanda Pharmaceuticals, Inc. | |
| US9138432 | February, 2016 |
Terminated-Denied
(30 Aug, 2016)
| Vanda Pharmaceuticals Inc. | Roxane Laboratories, Inc. |
Vanda Pharms Inc Drug Patents' Oppositions Filed in EPO
Vanda Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 21, 2022, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP15807916A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP15807916A | Oct, 2022 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP15807916A | Oct, 2022 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
Vanda Pharms Inc's Family Patents
Vanda Pharms Inc drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 29.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Vanda Pharms Inc Drug List
Given below is the complete list of Vanda Pharms Inc's drugs and the patents protecting them.
1. Fanapt
Fanapt is protected by 10 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9074254 | Method of predicting a predisposition to QT prolongation |
28 Dec, 2031
(7 years from now)
| Active |
| US9074256 | Method of predicting a predisposition to QT prolongation |
10 Feb, 2031
(6 years from now)
| Active |
| US9072742 | Method of predicting a predisposition to QT prolongation |
16 Jan, 2031
(6 years from now)
| Active |
| US9074255 | Method of predicting a predisposition to QT prolongation |
17 Dec, 2030
(6 years from now)
| Active |
| US8999638 | Method of treatment based on polymorphisms of the KCNQ1 gene |
28 Oct, 2030
(5 years from now)
| Active |
| US8652776 | Prediction of QT prolongation based on SNP genotype |
31 Aug, 2030
(5 years from now)
| Active |
| US9157121 | Method of treatment based on polymorphisms of the KCNQ1 gene |
05 Apr, 2030
(5 years from now)
| Active |
| US8586610 | Methods for the administration of iloperidone |
02 Nov, 2027
(2 years from now)
| Active |
| US9138432 | Methods for the administration of iloperidone |
30 Sep, 2025
(10 months from now)
| Active |
| USRE39198 | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics |
15 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fanapt's drug page
2. Hetlioz
Hetlioz is protected by 32 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759446 | Liquid tasimelteon formulations and methods of use thereof |
21 Feb, 2041
(16 years from now)
| Active |
| US10179119 | Method of treatment |
29 Aug, 2035
(10 years from now)
| Active |
| US11266622 | Method of treatment |
29 Aug, 2035
(10 years from now)
| Active |
| US10376487 | Method of treatment |
27 Jul, 2035
(10 years from now)
| Active |
| US10071977 | Highly purifid pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US10829465 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US11566011 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US11760740 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US12049457 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US10610511 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US11141400 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US11786502 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US9730910 | Treatment of circadian rhythm disorders |
17 May, 2034
(9 years from now)
| Active |
| US11918556 | Treatment of circadian rhythm disorders |
07 Apr, 2033
(8 years from now)
| Active |
| US10149829 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10449176 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10610510 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10945988 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10980770 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11285129 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11633377 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11826339 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11833130 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11850229 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11918557 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US8785492 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US9060995 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US9539234 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US9549913 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US9855241 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| USRE46604 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
09 Dec, 2022
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hetlioz's drug page
3. Hetlioz Lq
Hetlioz Lq is protected by 26 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11759446 | Liquid tasimelteon formulations and methods of use thereof |
21 Feb, 2041
(16 years from now)
| Active |
| US11202770 | Liquid tasimelteon formulations and methods of use thereof |
11 Dec, 2040
(16 years from now)
| Active |
| US10179119 | Method of treatment |
29 Aug, 2035
(10 years from now)
| Active |
| US11266622 | Method of treatment |
29 Aug, 2035
(10 years from now)
| Active |
| US10376487 | Method of treatment |
27 Jul, 2035
(10 years from now)
| Active |
| US10071977 | Highly purifid pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US10829465 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US11566011 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US11760740 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US12049457 | Highly purified pharmaceutical grade tasimelteon |
12 Feb, 2035
(10 years from now)
| Active |
| US10610511 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US11141400 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US11786502 | Method of treatment |
10 Oct, 2034
(9 years from now)
| Active |
| US9730910 | Treatment of circadian rhythm disorders |
17 May, 2034
(9 years from now)
| Active |
| US11918556 | Treatment of circadian rhythm disorders |
07 Apr, 2033
(8 years from now)
| Active |
| US10149829 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10610510 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US10980770 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11285129 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11633377 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11826339 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11833130 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11850229 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US11918557 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US9539234 | Treatment of circadian rhythm disorders |
25 Jan, 2033
(8 years from now)
| Active |
| US5856529 | Benzofuran and dihydrobenzofuran melatonergic agents |
09 Dec, 2022
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Hetlioz Lq's drug page
4. Ponvory
Ponvory is protected by 7 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11951097 | Methods of treating multiple sclerosis |
10 Oct, 2042
(17 years from now)
| Active |
| US10220023 | Dosing regimen for a selective S1P1 receptor agonist |
10 Dec, 2035
(11 years from now)
| Active |
| US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
06 May, 2032
(7 years from now)
| Active |
| US8273779 | Thiazolidin 4-one derivatives |
17 Dec, 2025
(1 year, 23 days from now)
| Active |
| USRE43728 | Thiazolidin-4-one derivatives |
16 Nov, 2025
(11 months from now)
| Active |
| US9000018 | Thiazolidin-4-one-derivatives |
16 Nov, 2024
(7 days ago)
| Expired |
| USRE43728 | Thiazolidin-4-one derivatives |
16 Nov, 2024
(7 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ponvory's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List